Ionis Pharmaceuticals (IONS) Competitors $41.34 -0.44 (-1.05%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$42.15 +0.81 (+1.96%) As of 07/8/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IONS vs. BIIB, INCY, UTHR, NBIX, EXEL, BMRN, EXAS, RGEN, MDGL, and HALOShould you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. Ionis Pharmaceuticals vs. Its Competitors Biogen Incyte United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Ionis Pharmaceuticals (NASDAQ:IONS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations. Do insiders and institutionals have more ownership in IONS or BIIB? 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.7% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer IONS or BIIB? In the previous week, Ionis Pharmaceuticals and Ionis Pharmaceuticals both had 8 articles in the media. Biogen's average media sentiment score of 0.91 beat Ionis Pharmaceuticals' score of 0.91 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, IONS or BIIB? Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIonis Pharmaceuticals$705M9.33-$453.90M-$2.99-13.83Biogen$9.68B2.04$1.63B$10.1313.27 Is IONS or BIIB more profitable? Biogen has a net margin of 15.07% compared to Ionis Pharmaceuticals' net margin of -63.65%. Biogen's return on equity of 14.03% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ionis Pharmaceuticals-63.65% -91.85% -15.77% Biogen 15.07%14.03%8.32% Do analysts recommend IONS or BIIB? Ionis Pharmaceuticals currently has a consensus target price of $58.25, suggesting a potential upside of 40.90%. Biogen has a consensus target price of $188.48, suggesting a potential upside of 40.18%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Ionis Pharmaceuticals is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ionis Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.78Biogen 0 Sell rating(s) 20 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.38 Which has more risk and volatility, IONS or BIIB? Ionis Pharmaceuticals has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. SummaryIonis Pharmaceuticals and Biogen tied by winning 8 of the 16 factors compared between the two stocks. Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IONS vs. The Competition Export to ExcelMetricIonis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.65B$2.39B$5.47B$8.95BDividend YieldN/A1.80%5.25%4.04%P/E Ratio-13.838.9826.9620.11Price / Sales9.33729.50430.20119.79Price / CashN/A159.8036.8257.86Price / Book11.084.517.985.56Net Income-$453.90M$31.26M$3.16B$248.40M7 Day Performance-5.16%3.57%2.39%4.67%1 Month Performance12.46%1.28%2.18%6.64%1 Year Performance-12.12%1.08%33.82%21.31% Ionis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IONSIonis Pharmaceuticals4.5947 of 5 stars$41.34-1.1%$58.25+40.9%-12.5%$6.65B$705M-13.831,069BIIBBiogen4.9562 of 5 stars$125.59-0.4%$188.48+50.1%-41.0%$18.40B$9.68B12.407,605INCYIncyte4.7635 of 5 stars$68.10-0.4%$74.53+9.4%+16.3%$13.18B$4.24B212.822,617Trending NewsInsider TradeUTHRUnited Therapeutics4.9946 of 5 stars$287.35+1.1%$386.15+34.4%-7.1%$12.96B$2.88B11.471,305Positive NewsAnalyst ForecastNBIXNeurocrine Biosciences4.9155 of 5 stars$125.69+0.2%$162.00+28.9%-9.5%$12.44B$2.36B42.611,800Positive NewsInsider TradeEXELExelixis4.7012 of 5 stars$44.08+0.9%$43.56-1.2%+97.0%$12.02B$2.17B20.041,147Trending NewsAnalyst ForecastOptions VolumeBMRNBioMarin Pharmaceutical4.9355 of 5 stars$54.97-0.4%$93.45+70.0%-29.9%$10.54B$2.85B20.443,040EXASExact Sciences4.9347 of 5 stars$53.14-1.0%$70.40+32.5%+18.5%$10.02B$2.83B-9.647,000Positive NewsAnalyst ForecastRGENRepligen4.7926 of 5 stars$124.38+0.7%$172.83+39.0%+7.3%$6.99B$634.44M-276.401,778Analyst ForecastMDGLMadrigal Pharmaceuticals4.0737 of 5 stars$302.64+0.6%$420.63+39.0%-1.1%$6.72B$317.38M-16.7790HALOHalozyme Therapeutics4.7712 of 5 stars$52.02-0.4%$61.90+19.0%+6.2%$6.41B$1.02B13.84390High Trading Volume Related Companies and Tools Related Companies BIIB Competitors INCY Competitors UTHR Competitors NBIX Competitors EXEL Competitors BMRN Competitors EXAS Competitors RGEN Competitors MDGL Competitors HALO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IONS) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IONS Stock Alerts